McDonald's Corp vs uniQure N.V. Ordinary Shares — how do they compare? McDonald's Corp trades at $241.57 (market cap $168.64B), while uniQure N.V. Ordinary Shares trades at $21.53 (market cap $1.45B). The key difference: McDonald's Corp is far larger — about 116.3× uniQure N.V. Ordinary Shares's market cap, and McDonald's Corp pays a 3.24% dividend while uniQure N.V. Ordinary Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold McDonald's Corp for 165 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| MCD | QURE | |
|---|---|---|
Market Cap | $168.64B | $1.45B |
Volume | 5,186,233 | 3,323,243 |
Sector | Consumer Cyclical | Health |
52-Week High | $341.06 | $70.59 |
52-Week Low | $230.88 | $9.03 |
Typical Hold Time | 165 Days | 0 Days |
Enterprise Value | $222.41B | $707.46M |
Dividend Yield | 3.24% | — |
Signals from Pluang's Aura AI — not financial advice
McDonald's (MCD) trades at $235.81, up 0.07% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $3.38 exceeding the $3.32 estimate. Revenue growth is steady, reaching $26.89B in 2025, while net income margin remains robust at 31.72%. Recent news highlights the launch of the 'McDonald's NEXT' strategy focusing on automation and menu innovation to drive growth.
The outlook is supported by analyst optimism with a consensus price target of $284.70, implying significant upside. However, risks include inflationary pressures on franchisee margins and high long-term debt of $38.42B. The stock presents a value opportunity with a P/E of 19.16, but investors should weigh execution risks against growth initiatives.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
McDonald's Corporation franchises and operates fast-food restaurants in the global restaurant industry. The Company's restaurants serves a variety of value-priced menu products in countries around the world.
Read more on MCD →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →